Elia Seguí

6PUBLICATIONS
74CO-AUTHORS
Molecular targetsPredictive and prognostic markersSolid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Sep 14, 2024
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

Elia Seguí, Juan Manuel Torres, Edouard Auclin

|Apr 13, 2024
Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment.

Marta García de Herreros, Juan Carlos Laguna, Joan Padrosa

|Sep 23, 2022
Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature.

Elia Seguí, Carles Zamora-Martínez, Tanny Daniela Barreto

|Sep 09, 2022
Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.

Giovanna Garufi, Luisa Carbognin, Francesco Schettini

Pageof 1

Frequent Collaborators

3 joint publications

Aleix Prat

2 joint publications

Carles Zamora-Martínez

2 joint publications

Joan Padrosa

2 joint publications

Juan Carlos Laguna